The complement system and adverse pregnancy outcomes

Molecular Immunology

Volumn 67, Issue 1, 2015, Pages 56-70

  Regal, Jean F ^a   Gilbert, Jeffrey S ^a   Burwick, Richard M ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Complement system; Fetal growth restriction; Miscarriage; Placenta; Preeclampsia; Pregnancy; Preterm birth

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOLIPID ANTIBODY; COMPLEMENT;

COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; FETUS DEVELOPMENT; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HOST RESISTANCE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PLACENTA DEVELOPMENT; PLACENTA MALARIA; PLASMA; PREGNANCY DISORDER; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE; ANIMAL; FEMALE; FETUS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MOUSE; MUTATION; PATHOLOGY; PLACENTA; PREGNANCY; PREMATURITY; RAT; STILLBIRTH;

RATTUS;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; FEMALE; FETAL GROWTH RETARDATION; FETUS; GENE EXPRESSION; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MICE; MUTATION; PLACENTA; PREGNANCY; PREMATURE BIRTH; RATS; STILLBIRTH;

EID: 84936985059     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.030     Document Type: Review

References (171)

1. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet. Gynecol. 2002, 99:159-167.
2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy. Obstet. Gynecol. 2013, 122:1122-1131. ACOG.
3. Aggarwal R., Sestak A.L., D'Sousa A., Dillon S.P., Namjou B., Scofield R.H. Complete complement deficiency in a large cohort of familial systemic lupus erythematosus. Lupus 2010, 19:52-57.
4. Agostinis C., Bossi F., Masat E., Radillo O., Tonon M., De Seta F., Tedesco F., Bulla R. MBL interferes with endovascular trophoblast invasion in pre-eclampsia. Clin. Dev. Immunol. 2012, 2012:484321.
5. Agostinis C., Bulla R., Tripodo C., Gismondi A., Stabile H., Bossi F., Guarnotta C., Garlanda C., De Seta F., Spessotto P., Santoni A., Ghebrehiwet B., Girardi G., Tedesco F. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J. Immunol. 2010, 185:4420-4429.
6. Agostinis C., Durigutto P., Sblattero D., Borghi M.O., Grossi C., Guida F., Bulla R., Macor P., Pregnolato F., Meroni P.L., Tedesco F. A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014, 123:3478-3487.
7. Albieri A., Kipnis T., Bevilacqua E. A possible role for activated complement component 3 in phagocytic activity exhibited by the mouse trophoblast. Am. J. Reprod. Immunol. 1999, 41:343-352.
8. Alper C.A. Inherited deficiencies of complement components in man. Immunol. Lett. 1987, 14:175-181.
9. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
10. Ananth C.V. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption. Semin. Perinatol. 2014, 38:131-132.
11. Ananth C.V., Keyes K.M., Wapner R.J. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013, 347:f6564.
12. Ananth C.V., Vintzileos A.M. Epidemiology of preterm birth and its clinical subtypes. J. Matern. Fetal Neonatal Med. 2006, 19:773-782.
13. Ananth C.V., Vintzileos A.M. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am. J. Obstet. Gynecol. 2006, 195:1557-1563.
14. Armstrong P.W., Granger C.B., Adams P.X., Hamm C., Holmes D., O'Neill W.W., Todaro T.G., Vahanian A., Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007, 297:43-51.
15. Baines M.G., Millar K.G., Mills P. Studies of complement levels in normal human pregnancy. Obstet. Gynecol. 1974, 43:806-810.
16. Bais J., Pel M., von dem Borne A., van der Lelie H. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur. J. Obstet. Gynecol. Reprod. Biol. 1994, 53:211-214.
17. Baj-Krzyworzeka M., Majka M., Pratico D., Ratajczak J., Vilaire G., Kijowski J., Reca R., Janowska-Wieczorek A., Ratajczak M.Z. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp. hematology 2002, 30:450-459.
18. Banadakoppa M., Chauhan M.S., Havemann D., Balakrishnan M., Dominic J.S., Yallampalli C. Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta. Clin. Exp. Immunol. 2014, 177:743-749.
19. Bates S.M., Greer I.A., Pabinger I., Sofaer S., Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:844S-886S.
20. Beasley K.M., Lovering A.T., Gilbert J.S. Decreased endothelial progenitor cells in preeclampsia and consequences for developmental programming. Hypertension 2014, 64:23-25.
21. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007, 335:974.
22. Birmingham D.J., Irshaid F., Nagaraja H.N., Zou X., Tsao B.P., Wu H., Yu C.Y., Hebert L.A., Rovin B.H. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010, 19:1272-1280.
23. Biryukov S., Stoute J.A. Complement activation in malaria: friend or foe?. Trends Mol. Med. 2014, 20:293-301.
24. Botto M., Kirschfink M., Macor P., Pickering M.C., Wurzner R., Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774-2783.
25. Bulla R., Agostinis C., Bossi F., Rizzi L., Debeus A., Tripodo C., Radillo O., De Seta F., Ghebrehiwet B., Tedesco F. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol. Immunol. 2008, 45:2629-2640.
26. Bulla R., Bossi F., Agostinis C., Radillo O., Colombo F., De Seta F., Tedesco F. Complement production by trophoblast cells at the feto-maternal interface. J. Reprod. Immunol. 2009, 82:119-125.
27. Bulla R., Bossi F., Tedesco F. The complement system at the embryo implantation site: friend or foe?. Front. Immunol. 2012, 3:55.
28. Burwick R.M., Burwick N.R., Feinberg B.B. Eculizumab fails to inhibit generation of C5a in vivo. Blood 2014, 124:3502-3503.
29. Burwick R.M., Easter S.R., Dawood H.Y., Yamamoto H.S., Fichorova R.N., Feinberg B.B. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension 2014, 64:833-838.
30. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013, 34:201-203.
31. Burwick R.M., Fichorova R.N., Dawood H.Y., Yamamoto H.S., Feinberg B.B. Urinary excretion of c5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013, 62:1040-1045.
32. Buurma A., Cohen D., Veraar K., Schonkeren D., Claas F.H., Bruijn J.A., Bloemenkamp K.W., Baelde H.J. Preeclampsia is characterized by placental complement dysregulation. Hypertension 2012, 60:1332-1337.
33. Buyon J.P., Cronstein B.N., Morris M., Tanner M., Weissmann G. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am. J. Med. 1986, 81:194-200.
34. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., Mele C., Bresin E., Cassis L., Gamba S., Porrati F., Bucchioni S., Monteferrante G., Fang C.J., Liszewski M.K., Kavanagh D., Atkinson J.P., Remuzzi G. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
35. Cataland S.R., Holers V.M., Geyer S., Yang S., Wu H.M. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014, 123:3733-3738.
36. Chaouat G., Petitbarat M., Bulla R., Dubanchet S., Valdivia K., Ledee N., Steffen T., Jensenius J.C., Tedesco F. Early regulators in abortion and implications for a preeclampsia model. J. Reprod. Immunol. 2009, 82:131-140.
37. Chiu Y.Y., Nisihara R.M., Wurzner R., Kirschfink M., de Messias-Reason I.J. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J. Investig. Allergol. Clin. Immunol. 1998, 8:239-244.
38. Chow W.N., Lee Y.L., Wong P.C., Chung M.K., Lee K.F., Yeung W.S. Complement 3 deficiency impairs early pregnancy in mice. Mol. Reprod. Dev. 2009, 76:647-655.
39. Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Meissner H.C., Baker C.J., Messonnier N.E. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2013, 62:1-28.
40. Conroy A.L., McDonald C.R., Silver K.L., Liles W.C., Kain K.C. Complement activation: a critical mediator of adverse fetal outcomes in placental malaria?. Trends Parasitol. 2011, 27:294-299.
41. Conroy A.L., Silver K.L., Zhong K., Rennie M., Ward P., Sarma J.V., Molyneux M.E., Sled J., Fletcher J.F., Rogerson S., Kain K.C. Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell Host Microbe 2013, 13:215-226.
42. Creanga A.A., Berg C.J., Syverson C., Seed K., Bruce F.C., Callaghan W.M. Pregnancy-related mortality in the United States, 2006-2010. Obstet. Gynecol. 2015, 125:5-12.
43. Crispi F., Dominguez C., Llurba E., Martin-Gallan P., Cabero L., Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am. J. Obstet. Gynecol. 2006, 195:201-207.
44. Crovetto F., Borsa N., Acaia B., Nishimura C., Frees K., Smith R.J., Peyvandi F., Palla R., Cugno M., Tedeschi S., Castorina P., Somigliana E., Ardissino G., Fedele L. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J. Matern. Fetal Neonatal Med. 2012, 25:2322-2325.
45. Cunningham D.S., Tichenor J.R. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin. Immunol. Immunopathol. 1995, 74:156-161.
46. Dantant M., Rivat C., Gilbert D., Fontaine M., Cavelier B., Godin M., Fillastre J.P. Selective deficiencies in complement component: a family with hereditary C2 deficiency. Biomedicine 1978, 28:185-190.
47. Dechend R., Gratze P., Wallukat G., Shagdarsuren E., Plehm R., Brasen J.H., Fiebeler A., Schneider W., Caluwaerts S., Vercruysse L., Pijnenborg R., Luft F.C., Muller D.N. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005, 45:742-746.
48. Derzsy Z., Prohaszka Z., Rigo J., Fust G., Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol. Immunol. 2010, 47:1500-1506.
49. Dixit R., Krieg A.M., Atkinson J.P. Thrombotic thrombocytopenic purpura developing during pregnancy in a C2-deficient patient with a history of systemic lupus erythematosus. Arthritis Rheum. 1985, 28:341-344.
50. Espinoza J., Romero R., Nien J.K., Gomez R., Kusanovic J.P., Goncalves L.F., Medina L., Edwin S., Hassan S., Carstens M., Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am. J. Obstet. Gynecol. 2007, 196(326):e1-e13.
51. Fakhouri F., Jablonski M., Lepercq J., Blouin J., Benachi A., Hourmant M., Pirson Y., Durrbach A., Grunfeld J.P., Knebelmann B., Fremeaux-Bacchi V. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 2008, 112:4542-4545.
52. Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L., Essig M., Ribes D., Dragon-Durey M.A., Bridoux F., Rondeau E., Fremeaux-Bacchi V. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 2010, 21:859-867.
53. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K., Pianetti G., Noris M., Goodship T.H., Atkinson J.P. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 111:624-632.
54. Fang C.J., Richards A., Liszewski M.K., Kavanagh D., Atkinson J.P. Advances in understanding of pathogenesis of aHUS and HELLP. Br. J. Haematol. 2008, 143:336-348.
55. Faulk W.P., Jarret R., Keane M., Johnson P.M., Boackle R.J. Immunological studies of human placentae: complement components in immature and mature chorionic villi. Clin. Exp. Immunol. 1980, 40:299-305.
56. Faulk W.P., Johnson P.M. Immunological studies of human placentae: identification and distribution of proteins in mature chorionic villi. Clin. Exp. Immunol. 1977, 27:365-375.
57. Fieni S., Bonfanti L., Gramellini D., Benassi L., Delsignore R. Clinical management of paroxysmal nocturnal hemoglobinuria in pregnancy: a case report and updated review. Obstet. Gynecol. Surv. 2006, 61:593-601.
58. Figueroa J.E., Densen P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 1991, 4:359-395.
59. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., Taylor S.M. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 1999, 42:1965-1974.
60. Friedman A.M., Cleary K.L. Prediction and prevention of ischemic placental disease. Semin. Perinatol. 2014, 38:177-182.
61. Garite T.J., Clark R., Thorp J.A. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am. J. Obstet. Gynecol. 2004, 191:481-487.
62. Garlatti V., Chouquet A., Lunardi T., Vives R., Paidassi H., Lortat-Jacob H., Thielens N.M., Arlaud G.J., Gaboriaud C. Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain. J. Immunol. 2010, 185:808-812.
63. Ghidini A. Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation. Prenat. Diagn. 2014, 34:649-654.
64. Girardi G. Complement inhibition keeps mothers calm and avoids fetal rejection. Immunol. Invest. 2008, 37:645-659.
65. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., Hollmann T.J., Casali P., Caroll M.C., Wetsel R.A., Lambris J.D., Holers V.M., Salmon J.E. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 2003, 112:1644-1654.
66. Girardi G., Fraser J., Lennen R., Vontell R., Jansen M., Hutchison G. Imaging of activated complement using ultrasmall superparamagnetic iron oxide particles (USPIO) - conjugated vectors: an in vivo in utero non-invasive method to predict placental insufficiency and abnormal fetal brain development. Mol. Psychiatry 2014, Sep 23 [Epub ahead of print]. 10.1038/mp.2014.110.
67. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 2004, 10:1222-1226.
68. Girardi G., Yarilin D., Thurman J.M., Holers V.M., Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 2006, 203:2165-2175.
69. Goldenberg R.L., Culhane J.F., Iams J.D., Romero R. Epidemiology and causes of preterm birth. Lancet 2008, 371:75-84.
70. Gonzalez J.M., Dong Z., Romero R., Girardi G. Cervical remodeling/ripening at term and preterm delivery: the same mechanism initiated by different mediators and different effector cells. PLoS ONE 2011, 6:e26877.
71. Gonzalez J.M., Franzke C.W., Yang F., Romero R., Girardi G. Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am. J. Pathol. 2011, 179:838-849.
72. Gonzalez J.M., Romero R., Girardi G. Comparison of the mechanisms responsible for cervical remodeling in preterm and term labor. J. Reprod. Immunol. 2013, 97:112-119.
73. Gou S.J., Yuan J., Wang C., Zhao M.H., Chen M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol. 2013, 8:1884-1891.
74. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 2014, 61:110-117.
75. Guseh S.H., Feinberg B.B., Dawood H.Y., Yamamoto H.S., Fichorova R.N., Burwick R.M. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am. J. Reprod. Immunol. 2014, Dec 17. [Epub ahead of print]. 10.1111/aji.12349.
76. Haeger M., Unander M., Bengtsson A. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet. Gynecol. 1990, 76:698-702.
77. Hallstensen R.F., Bergseth G., Foss S., Jaeger S., Gedde-Dahl T., Holt J., Christiansen D., Lau C., Brekke O.L., Armstrong E., Stefanovic V., Andersen J.T., Sandlie I., Mollnes T.E. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2014, 220:452-459.
78. Hellerud B.C., Aase A., Herstad T.K., Naess L.M., Kristiansen L.H., Troseid A.M., Harboe M., Lappegard K.T., Brandtzaeg P., Hoiby E.A., Mollnes T.E. Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies. Infect. Immun. 2010, 78:802-809.
79. Hering L., Herse F., Verlohren S., Park J.K., Wellner M., Qadri F., Pijnenborg R., Staff A.C., Huppertz B., Muller D.N., Luft F.C., Dechend R. Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension 2008, 51:554-559.
80. Holmes C.H., Simpson K.L., Okada H., Okada N., Wainwright S.D., Purcell D.F., Houlihan J.M. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur. J. Immunol. 1992, 22:1579-1585.
81. Holmes C.H., Simpson K.L., Wainwright S.D., Tate C.G., Houlihan J.M., Sawyer I.H., Rogers I.P., Spring F.A., Anstee D.J., Tanner M.J. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J. Immunol. 1990, 144:3099-3105.
82. Hsi B.L., Hunt J.S., Atkinson J.P. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J. Reprod. Immunol. 1991, 19:209-223.
83. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
84. Iams J.D. Preterm birth categories - labels with consequences. Am. J. Obstet. Gynecol. 2014, 210:97-98.
85. Irving F.C. A study of five hundred consecutive cases of pre-eclampsia. Can. Med. Assoc. J. 1939, 40:137-140.
86. Jonsson G., Sjoholm A.G., Truedsson L., Bengtsson A.A., Braconier J.H., Sturfelt G. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology (Oxford) 2007, 46:1133-1139.
87. Kelly R., Arnold L., Richards S., Hill A., Bomken C., Hanley J., Loughney A., Beauchamp J., Khursigara G., Rother R.P., Chalmers E., Fyfe A., Fitzsimons E., Nakamura R., Gaya A., Risitano A.M., Schubert J., Norfolk D., Simpson N., Hillmen P. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br. J. Haematol. 2010, 149:446-450.
88. Kimura Y., Zhou L., Miwa T., Song W.C. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J. Clin. Invest. 2010, 120:3545-3554.
89. Kitzmiller J.L., Stoneburner L., Yelenosky P.F., Lucas W.E. Serum complement in normal pregnancy and pre-eclampsia. Am. J. Obstet. Gynecol. 1973, 117:312-315.
90. Kolev M., Le Friec G., Kemper C. Complement - tapping into new sites and effector systems. Nat. Rev. Immunol. 2014, 14:811-820.
91. Kupferminc M., Rimon E., Many A., Maslovitz S., Lessing J.B., Gamzu R. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul. Fibrinol. 2011, 22:123-126.
92. Kusakabe K., Naka M., Ito Y., Eid N., Otsuki Y. Regulation of natural-killer cell cytotoxicity and enhancement of complement factors in the spontaneously aborted mouse placenta. Fertil. Steril. 2008, 90:1451-1459.
93. LaMarca B., Cornelius D., Wallace K. Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda) 2013, 28:225-233.
94. Lee Y.L., Cheong A.W., Chow W.N., Lee K.F., Yeung W.S. Regulation of complement-3 protein expression in human and mouse oviducts. Mol. Reprod. Dev. 2009, 76:301-308.
95. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2013, 368:2169-2181.
96. Lewandowski A.J., Davis E.F., Yu G., Digby J.E., Boardman H., Whitworth P., Singhal A., Lucas A., McCormick K., Shore A.C., Leeson P. Elevated blood pressure in preterm-born offspring associates with a distinct antiangiogenic state and microvascular abnormalities in adult life. Hypertension 2014, 65:607-614.
97. Lewandowski A.J., Leeson P. Preeclampsia, prematurity and cardiovascular health in adult life. Early Hum. Dev. 2014, 90:725-729.
98. Lillegard K.E., Johnson A.C., Lojovich S.J., Bauer A.J., Marsh H.C., Gilbert J.S., Regal J.F. Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol. Immunol. 2013, 56:91-97.
99. Lillegard K.E., Loeks-Johnson A.C., Opacich J.W., Peterson J.M., Bauer A.J., Elmquist B.J., Regal R.R., Gilbert J.S., Regal J.F. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. J. Pharmacol. Exp. Ther. 2014, 351:344-351.
100. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 2011, 6:60.
101. Lokki A.I., Heikkinen-Eloranta J., Jarva H., Saisto T., Lokki M.L., Laivuori H., Meri S. Complement activation and regulation in preeclamptic placenta. Front. Immunol. 2014, 5. Article 312.
102. Lood C., Tyden H., Gullstrand B., Sturfelt G., Jonsen A., Truedsson L., Bengtsson A.A. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS ONE 2014, 9:e99386.
103. Lynch A.M., Gibbs R.S., Murphy J.R., Byers T., Neville M.C., Giclas P.C., Salmon J.E., Van Hecke T.M., Holers V.M. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am. J. Obstet. Gynecol. 2008, 199(354):e1-e8.
104. Lynch A.M., Gibbs R.S., Murphy J.R., Giclas P.C., Salmon J.E., Holers V.M. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet. Gynecol. 2011, 117:75-83.
105. Mao D., Wu X., Deppong C., Friend L.D., Dolecki G., Nelson D.M., Molina H. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity 2003, 19:813-822.
106. Martel C., Granger C.B., Ghitescu M., Stebbins A., Fortier A., Armstrong P.W., Bonnefoy A., Theroux P. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am. Heart J. 2012, 164:43-51.
107. Marto N., Bertolaccini M.L., Calabuig E., Hughes G.R., Khamashta M.A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:444-448.
108. Mayer A.E., Parks G.D. An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester. PLoS ONE 2014, 9:e112749.
109. McElroy J.J., Gutman C.E., Shaffer C.M., Busch T.D., Puttonen H., Teramo K., Murray J.C., Hallman M., Muglia L.J. Maternal coding variants in complement receptor 1 and spontaneous idiopathic preterm birth. Hum. Genet. 2013, 132:935-942.
110. Meyer O., Hauptmann G., Tappeiner G., Ochs H.D., Mascart-Lemone F. Genetic deficiency of C4, C2 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin. Exp. Immunol. 1985, 62:678-684.
111. Millar K.G., Mills P. C 1 3 and IgG levels in mothers and babies at delivery. Obstet. Gynecol. 1972, 39:527-532.
112. Mohlin F.C., Mercier E., Fremeaux-Bacchi V., Liszewski M.K., Atkinson J.P., Gris J.C., Blom A.M. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur. J. Immunol. 2013, 43:1617-1629.
113. Moore M.P., Redman C.W. Case-control study of severe pre-eclampsia of early onset. Br. Med. J. (Clin. Res. Ed.) 1983, 287:580-583.
114. Muehlenbachs A., Mutabingwa T.K., Edmonds S., Fried M., Duffy P.E. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med. 2006, 3:e446.
115. Munoz-Hernandez R., Miranda M.L., Stiefel P., Lin R.Z., Praena-Fernandez J.M., Dominguez-Simeon M.J., Villar J., Moreno-Luna R., Melero-Martin J.M. Decreased level of cord blood circulating endothelial colony-forming cells in preeclampsia. Hypertension 2014, 64:165-171.
116. Naik A., Sharma S., Quigg R.J. Complement regulation in renal disease models. Semin. Nephrol. 2013, 33:575-585.
117. Ndao C.T., Dumont A., Fievet N., Doucoure S., Gaye A., Lehesran J.Y. Placental malarial infection as a risk factor for hypertensive disorders during pregnancy in Africa: a case-control study in an urban area of Senegal, West Africa. Am. J. Epidemiol. 2009, 170:847-853.
118. Nelson D.B., Ziadie M.S., McIntire D.D., Rogers B.B., Leveno K.J. Placental pathology suggesting that preeclampsia is more than one disease. Am. J. Obstet. Gynecol. 2014, 210(66):e1-e7.
119. Newnham J.P., Dickinson J.E., Hart R.J., Pennell C.E., Arrese C.A., Keelan J.A. Strategies to prevent preterm birth. Front. Immunol. 2014, 5:584.
120. NHLBI Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 2000, 183:S1-S22.
121. Nishikori K., Noma J., Hirakawa S., Amano T., Kudo T. The change of membrane complement regulatory protein in chorion of early pregnancy. Clin. Immunol. Immunopathol. 1993, 69:167-174.
122. Noris M., Remuzzi G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin. Nephrol. 2010, 30:395-408.
123. Nowicki S., Izban M.G., Pawelczyk E., Agboto V.K., Pratap S., Olson G., Nowicki B. Preterm labor: CD55 in maternal blood leukocytes. Am. J. Reprod. Immunol. 2009, 61:360-367.
124. Oberkersch R., Attorresi A.I., Calabrese G.C. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb. Res. 2010, 125:e240-e245.
125. Pacheco L.D., Hankins G.D., Costantine M.M., Anderson G.D., Pawelczyk E., Nowicki S., Nowicki B.J. The role of human decay-accelerating factor in the pathogenesis of preterm labor. Am. J. Perinatol. 2011, 28:565-570.
126. Paruk F., Moodley J. Maternal and neonatal outcome in early- and late-onset pre-eclampsia. Semin. Neonatol. 2000, 5:197-207.
127. Pedroni S.M., Gonzalez J.M., Wade J., Jansen M.A., Serio A., Marshall I., Lennen R.J., Girardi G. Complement inhibition and statins prevent fetal brain cortical abnormalities in a mouse model of preterm birth. Biochim. Biophys. Acta 2014, 1842:107-115.
128. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R., Xhaard A., Rosain J., Cadena Castaneda D., Vieira-Martins P., Roncelin S., Rodriguez-Otero P., Plessier A., Sicre de Fontbrune F., Abbes S., Robin M., Socie G. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2014, 125:775-783.
129. Petersen B.H., Lee T.J., Snyderman R., Brooks G.F. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann. Intern. Med. 1979, 90:917-920.
130. Pinheiro C.C., Rayol P., Gozzani L., Reis L.M., Zampieri G., Dias C.B., Woronik V. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia. Prenat. Diagn. 2014, 34:1084-1092.
131. Prall R.H., Kantor F.S. Serum complement in eclamptogenic toxemia. Am. J. Obstet. Gynecol. 1966, 95:530-533.
132. Pratap S., Brown L.E., Izban M.G., Nowicki S., Nowicki B.J. Accurate preterm labor diagnosis using a CD55-TLR4 combination biomarker model. J. Biomed. Sci. Eng. 2013, 6:253-257.
133. Proctor L.M., Arumugam T.V., Shiels I., Reid R.C., Fairlie D.P., Taylor S.M. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 2004, 142:756-764.
134. Qing X., Redecha P.B., Burmeister M.A., Tomlinson S., D'Agati V.D., Davisson R.L., Salmon J.E. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011, 79:331-339.
135. Qu X.W., Jilling T., Neerhof M.G., Luo K., Hirsch E., Thaete L.G. Unilateral uterine ischemia/reperfusion-induced bilateral fetal loss and fetal growth restriction in a murine model require intact complement component 5. J. Reprod. Immunol. 2012, 95:27-35.
136. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
137. Ratajczak J., Reca R., Kucia M., Majka M., Allendorf D.J., Baran J.T., Janowska-Wieczorek A., Wetsel R.A., Ross G.D., Ratajczak M.Z. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 2004, 103:2071-2078.
138. Ray J.G., Burows R.F., Ginsberg J.S., Burrows E.A. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000, 30:103-117.
139. Reca R., Mastellos D., Majka M., Marquez L., Ratajczak J., Franchini S., Glodek A., Honczarenko M., Spruce L.A., Janowska-Wieczorek A., Lambris J.D., Ratajczak M.Z. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003, 101:3784-3793.
140. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110:2423-2431.
141. Richani K., Soto E., Romero R., Espinoza J., Chaiworapongsa T., Nien J.K., Edwin S., Kim Y.M., Hong J.S., Mazor M. Normal pregnancy is characterized by systemic activation of the complement system. J. Matern. Fetal Neonatal Med. 2005, 17:239-245.
142. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 2013, 190:3839-3847.
143. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 2013, 735:1-22.
144. Risitano A.M., Ricklin D., Huang Y., Reis E.S., Chen H., Ricci P., Lin Z., Pascariello C., Raia M., Sica M., Del Vecchio L., Pane F., Lupu F., Notaro R., Resuello R.R., DeAngelis R.A., Lambris J.D. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123:2094-2101.
145. Roberts J.M. Pathophysiology of ischemic placental disease. Semin. Perinatol. 2014, 38:139-145.
146. Romay-Penabad Z., Carrera Marin A.L., Willis R., Weston-Davies W., Machin S., Cohen H., Brasier A., Gonzalez E.B. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 2014, 23:1324-1326.
147. Romero R., Dey S.K., Fisher S.J. Preterm labor: one syndrome, many causes. Science 2014, 345:760-765.
148. Saadoun S., Waters P., Leite M.I., Bennett J.L., Vincent A., Papadopoulos M.C. Neuromyelitis optica IgG causes placental inflammation and fetal death. J. Immunol. 2013, 191:2999-3005.
149. Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008, 371:261-269.
150. Salmon J.E., Heuser C., Triebwasser M., Liszewski M.K., Kavanagh D., Roumenina L., Branch D.W., Goodship T., Fremeaux-Bacchi V., Atkinson J.P. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011, 8:e1001013.
151. Shibata E., Rajakumar A., Powers R.W., Larkin R.W., Gilmour C., Bodnar L.M., Crombleholme W.R., Ness R.B., Roberts J.M., Hubel C.A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab. 2005, 90:4895-4903.
152. Singh J., Ahmed A., Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011, 58:716-724.
153. Soares M.J., Chakraborty D., Karim Rumi M.A., Konno T., Renaud S.J. Rat placentation: an experimental model for investigating the hemochorial maternal-fetal interface. Placenta 2012, 33:233-243.
154. Song W.C. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 2012, 40:174-182.
155. Soto E., Romero R., Richani K., Espinoza J., Chaiworapongsa T., Nien J.K., Edwin S.S., Kim Y.M., Hong J.S., Goncalves L.F., Yeo L., Mazor M., Hassan S.S., Kusanovic J.P. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J. Matern. Fetal Neonatal Med. 2010, 23:646-657.
156. Soto E., Romero R., Richani K., Espinoza J., Nien J.K., Chaiworapongsa T., Santolaya-Forgas J., Edwin S.S., Mazor M. Anaphylatoxins in preterm and term labor. J. Perinat. Med. 2005, 33:306-313.
157. Stohl W., Hiepe F., Latinis K.M., Thomas M., Scheinberg M.A., Clarke A., Aranow C., Wellborne F.R., Abud-Mendoza C., Hough D.R., Pineda L., Migone T.S., Zhong Z.J., Freimuth W.W., Chatham W.W. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012, 64:2328-2337.
158. Sullivan K.E., Winkelstein J.A. Prenatal diagnosis of heterozygous deficiency of the second component of complement. Clin. Diagn. Lab. Immunol. 1994, 1:606-607.
159. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 1997, 185:1619-1627.
160. Tedesco F., Radillo O., Candussi G., Nazzaro A., Mollnes T.E., Pecorari D. Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin. Exp. Immunol. 1990, 80:236-240.
161. Tichenor J.R., Bledsoe L.B., Opsahl M.S., Cunningham D.S. Activation of complement in humans with a first-trimester pregnancy loss. Gynecol. Obstet. Invest. 1995, 39:79-82.
162. Usami M., Mitsunaga K., Miyajima A., Sunouchi M., Doi O. Complement component C3 functions as an embryotrophic factor in early postimplantation rat embryos. Int. J. Dev. Biol. 2010, 54:1277-1285.
163. Vaisbuch E., Romero R., Erez O., Mazaki-Tovi S., Kusanovic J.P., Soto E., Dong Z., Chaiworapongsa T., Kim S.K., Ogge G., Pacora P., Yeo L., Hassan S.S. Activation of the alternative pathway of complement is a feature of pre-term parturition but not of spontaneous labor at term. Am. J. Reprod. Immunol. 2010, 63:318-330.
164. van de Geijn F.E., Roos A., de Man Y.A., Laman J.D., de Groot C.J., Daha M.R., Hazes J.M., Dolhain R.J. Mannose-binding lectin levels during pregnancy: a longitudinal study. Hum. Reprod. 2007, 22:362-371.
165. Veerbeek J.H., Hermes W., Breimer A.Y., van Rijn B.B., Koenen S.V., Mol B.W., Franx A., de Groot C.J., Koster M.P. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension 2015, 65:600-606.
166. Vogel C.W., Finnegan P.W., Fritzinger D.C. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Mol. Immunol. 2014, 61:191-203.
167. Wang W., Irani R.A., Zhang Y., Ramin S.M., Blackwell S.C., Tao L., Kellems R.E., Xia Y. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012, 60:712-721.
168. Wathen K.A., Tuutti E., Stenman U.H., Alfthan H., Halmesmaki E., Finne P., Ylikorkala O., Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 2006, 91:180-184.
169. Weisman H.F., Bartow T., Leppo M.K., Boyle M.P., Marsh H.C., Carson G.R., Roux K.H., Weisfeldt M.L., Fearon D.T. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans. Assoc. Am. Physicians 1990, 103:64-72.
170. Wells M., Bennett J., Bulmer J.N., Jackson P., Holgate C.S. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. J. Reprod. Immunol. 1987, 12:125-135.
171. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.